Psoriatic arthritis
Immunology· 10 reviewed drugs· 28897 cited findings behind them
What the regulatory reviews cover
Regulatory review documents in this library for psoriatic arthritis include Tremfya, Bimzelx, Cosentyx, Skyrizi, Sotyktu, Xeljanz, Otezla, and Nordimet. These reviews detail various efficacy and safety outcomes. For instance, Tremfya's review noted a Clinical remission (primary endpoint) with statistically significant results. Bimzelx's review reported a PASI 90 response rate of 90.8, while the placebo group had a PASI 90 response rate of 4.8. Otezla demonstrated an ACR20 response rate of 38 compared to 19 for placebo. Nordimet's review showed a PASI 75 response rate of 41, with the placebo group at 10.
It is important to note that these drugs were studied in different clinical trials, and therefore, the reported figures are not directly comparable in a head-to-head manner. Each drug's review provides specific data points relevant to its individual study design and patient population.
The drugs — one cited result each
| Tremfya Johnson & Johnson | Clinical remission (primary endpoint): statistically significant results JANSSEN BIOTECH — Tremfya FDA Review, p.110 |
| Bimzelx UCB SA | PASI 90 response rate: 90.8 UCB S A — Bimzelx EMA EPAR public assessment report (EMEA/H/, p.214 |
| Cosentyx Novartis AG | PASI 75 response: 95 NOVARTIS PHARMS CORP — Cosentyx FDA Review (NDA/BLA 125504,, p.26 |
| Skyrizi AbbVie Inc. | ACR20 Response Rate (%): 33.4 ABBVIE INC — Skyrizi FDA Review (NDA/BLA 761105, 2024), p.22 |
| Humira AbbVie Inc. | 3502 cited findings on the drug page → |
| Sotyktu Bristol-Myers Squibb Company | Statistical significance for co-primary endpoints (sPGA 0/1 and PASI 75): achieved Bristol-Myers Squibb Company — Sotyktu EMA EPAR public asses, p.112 |
| Xeljanz Pfizer Inc. | Recommended dosage for Psoriatic Arthritis: 5 mg twice daily PF PRISM CV — Xeljanz FDA Review (NDA/BLA 203214, 2022), p.13 |
| Otezla Amgen Inc. | ACR20 response rate: 38 AMGEN INC — Otezla FDA Review (NDA/BLA 205437, 2026), p.18 |
| Cimzia UCB SA | 917 cited findings on the drug page → |
| Nordimet Nordic B V | PASI 75 response rate: 41 Nordic B V — Nordimet EMA EPAR variation assessment report (, p.20 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Immunology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.